Jefferies Maintains Hold Rating on United Therapeutics

Jefferies is maintaining its Hold rating on shares of United Therapeutics Corp. UTHR. “Lower-than-expected 6MWD improvement with oral treprostinil in FREEDOMM, albeit hitting statistical significance, places pressure on second Ph3 study (FREEDOM-C2; data in Sept),” Jefferies writes. “We view FREEDOM-C2 success as important for commercial success of oral treprostinil.” United Therapeutics closed Monday at $59.00.